The study's innovation lies in its pioneering use of S1PR1 PET probe [18F]TZ4877 to evaluate the efficacy of EA treatment in AD, underscoring the potential clinical utility of targeting S1PR1 PET in the diagnosis and treatment of AD. Here, S1PR1 is linked to Alzheimer disease.